PMS-SITAGLIPTIN TARTRATE/METFORMIN DIN 02535238
Status: Cancelled Pre Market
Holder: PHARMASCIENCE INC
Health Canada record
| Active ingredient(s) | SITAGLIPTIN (SITAGLIPTIN TARTRATE HEMIHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 850 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | A10BD07 METFORMIN AND SITAGLIPTIN |
| Original market date | |
| Current status date | 31-Jul-2026 |
| Source | Health Canada DPD |
Establishment licence of the holder
Pharmascience Inc. — licence 100241, currently licensed, last inspection rating C (2025-03-20).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing SITAGLIPTIN (SITAGLIPTIN TARTRATE HEMIHYDRATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02545705 | RIVA-SITAGLIPTIN TARTRATE/METFORMIN | LABORATOIRE RIVA INC. | Tablet | SITAGLIPTIN (SITAGLIPTIN TARTRATE HEMIHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 850 MG | Approved |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 30074 | 2023-02-08 | Abbreviated New Drug Submission (ANDS) |